Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Basilea partner Asahi Kasei starts phase 2 study of Cresemba in children in Japan
Asahi Kasei Therapeutics has started a multicenter, open‑label phase 2 study in Japan of Cresemba (isavuconazole) in children at risk for invasive mycoses to evaluate safety and pharmacokinetics. Cresemba is already approved for pediatric patients in the US, Canada, Europe and China, but in Japan it is so far approved only for adults. Worldwide in‑market sales of Cresemba amounted to USD 782 million in the April 2025–March 2026 period. » More on finanzen.net
Asahi Kasei secures license for Noguchi ADC technology
Asahi Kasei Life Science has acquired licensing rights for an ADC technology developed by the Noguchi Institute that enables control of drug–antibody ratio and binding sites and the conjugation of two different drugs to a single antibody. The partners plan joint research, commercialization and possible sublicensing to biopharma companies and CDMOs such as Bionova Scientific. Asahi Kasei will thereby strengthen its healthcare offering; InvestingPro rates the company as financially very strong and sees upside potential for the share price. » More on de.investing.com
Asahi Kasei acquires Aicuris for €780 million
Asahi Kasei has signed a definitive agreement to acquire all shares of Aicuris Anti-infective Cures for around €780 million; closing is expected in the first quarter of fiscal 2026. The acquisition expands Asahi Kasei’s specialty pharma portfolio with three assets, including the already licensed Prevymis, Pritelivir — which is nearing FDA approval with a 2026 target — and AIC468, currently in Phase I with a planned launch in 2030. Asahi Kasei expects the transaction to contribute positively to operating income from fiscal 2028 after amortization, strengthening its position in transplantation, nephrology and severe infectious diseases. » More on de.investing.com
Asahi Kasei secures global exclusive license for novel agents against autoimmune diseases
Asahi Kasei Pharma has signed an exclusive global licensing agreement with Alchemedicine for preclinical lead compounds to treat autoimmune diseases, obtaining worldwide rights for research, development, manufacturing and commercialization. The substances were identified using Alchemedicine’s HiSAP platform; the program is independent of a prior 2022 collaboration. The compound AK1960 was recently advanced into a phase‑I study. Asahi Kasei emphasizes its “open innovation” strategy to develop therapy candidates and strengthen its pharma growth target through 2030. » More on de.investing.com
Asahi Kasei increases earnings per share and revenue in latest quarter
Asahi Kasei reported earnings per share of 40.03 JPY for the latest quarter, up from 27.65 JPY in the year‑ago quarter. Revenue was 774.90 billion JPY, an increase of 0.78% from 768.92 billion JPY in the year‑ago quarter. The figures come from the quarterly financial conference on February 4, 2026. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 4.84bn | 12.33% |
| Gross profit | 1.63bn | 16.09% |
| Net profit | 271.38m | 1.25% |
| EBITDA | 777.15m | 10.54% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.85bn |
Number of shares | 1.33bn |
52-week high/low | €10.90 - €7.13 |
Dividend yield | 2.47% |
Dividends TTM | €0.23 |
Next dividend | €0.14 |
Beta | 0.67 |
P/E ratio | 10.78 |
PEG ratio | 0.27 |
P/B ratio | 1.00 |
P/S ratio | 0.63 |
Company profile
Asahi Kasei Corporation manufactures, processes, and sells chemical products in Japan and internationally. The company operates through three segments: Material, Homes, and Health Care. It provides caustic soda, chemical fertilizers, nitric acid, ammonia, acrylonitrile, methyl methacrylate, styrene, adipic acid, hexamethylene diamine, AH salt, propionitrile, sodium cyanide, acetonitrile, methacrylonitrile, cyclohexyl methacrylate, cyclohexanol, cyclohexane, and cyclohexene; polymers; chemical intermediates; additives; membranes and systems; clads and anchors; optical and printing materials; electronic materials; and lithium-ion battery and lead-acid battery separators. The company offers cupro fiber, lining fabric, stretch fiber, spunbond nonwovens, cupro nonwoven fabric, microfiber suede, oil-water separator, multifunctional nonwoven, deodorizing nonwoven, heat-press formable thermoplastic nonwoven, noise suppression sheet, nylon filaments, flame-resistant fiber, honeycomb fabric, cellulose nanobead, ecorise, biocradle, and bemliese products, as well as polymers; synthetic rubber; elastomers; kitchen and household products; cleaners; and packaging products. In addition, the company provides electronic devices; and autoclaved aerated concrete, foundation systems, insulation materials, and structural systems and components. Further, it involved in the construction of homes and apartments; management of rental units and condominiums; brokerage of used homes; remodeling; and mortgage financing, asset management services, and insurance products. Additionally, the company provides pharmaceuticals and diagnostic reagents; dialyzers; therapeutic apheresis; biotherapeutics and plasma derivative filters and equipment, and virus removal filters; leukocyte reduction filters; defibrillators, temperature management systems, and data solutions; and UVC LED products. Asahi Kasei Corporation was founded in 1922 and is headquartered in Tokyo, Japan.
| Name | Asahi Kasei |
| CEO | Koshiro Kudo |
| Headquarters | Tokyo,
ty Japan |
| Website | |
| IPO | 04/01/2000 |
| Employees | 47,895 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Japan Exchange Group | 3407.T |
Pnk | AHKSF |
Frankfurt | ASAA.F |
DĂĽsseldorf | ASAA.DU |
MĂĽnchen | ASAA.MU |